All news

Merck beats estimates, lifts profit outlook on Keytruda strength

CNBC · RSS · · AI-summarised by FinFlash

Merck topped quarterly estimates and raised its profit outlook, helped by stronger-than-expected sales of its immunotherapy Keytruda, including a newer injectable form of the drug. The results point to resilient demand across the company's cancer franchise as it works to extend Keytruda's lifecycle. For investors, the raised guidance signals management expects earnings momentum to continue.

Read original source

MRK company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.